Curiel, Tyler JaySchool of Medicine |
|
|
I am a physician-scientist with clinical expertise in phase I experimental therapeutics and gynecologic cancers. My laboratory expertise is in human immunology with an emphasis on understanding the immunopathologic basis of human diseases including cancer, infections and autoimmunity. I have significant administrative expertise as past chief of two different academic divisions of hematology and medical oncology, director of a general clinical research center and executive director of an NCI-designated cancer center. I translate my groups discoveries into novel clinical trials. I have been funded by the NIH and other entities since 1987. |
|
| 8/2006 - Present | Professor of Medicine | UTHSCSA, Medicine, San Antonio, TX |
| Year | Degree | Discipline | Institution |
| 1997 | Postdoctoral Fellowship | Medical Oncology | University of Colorado Health Sciences Center Denver , CO |
| 1990 | Postdoctoral Fellowship | Infectious Disease | Harvard Medical School & Massachusetts General Hospital Boston , MA |
| 1990 | Postdoctoral Fellowship | Medicine | Harvard Medical School Boston , MA |
| 1986 | Residency | Internal Medicine | Yale Medical School & Yale-New Haven Hospital New Haven , CT |
| 1984 | Internship | Medicine | Yale Medical School & Yale-New Haven Hospital New Haven , CT |
| 1983 | MPH | Epidemiology/Biostatistics | Harvard University Boston , MA |
| 1982 | MD | Medicine | Duke Medical School Durham , NC |
| 1977 | BS | Chemistry (summa cum laude, with highest honors, with honors in chemistry) | University of Georgia Athens , GA |
| My group and I are focused on finding optimal means to use immune therapy to treat a variety of immunopathologic conditions including cancers, infections and autoimmunity. We study immune dysregulation underlying immunopathologic states in mouse models and human patients and undertake clinical trials of our own findings. Current work focuses on the role of immune regulatory cells and dendritic cells in immunopathology and sexual dimorphisms in the functions of these cells. |
| Date | Description | Institution | # Students |
| 8/2012 - Present | Pre-Doctoral Student Supervision | UTHSCSA | |
| 1/2010 - Present | Refugee clinic | ||
| 1/2009 - Present | "Fronteras" Preceptor to first and second year UTHSCSA medical students | UTHSCSA | |
| 1/2009 - Present | Clinical Preceptor for first and second year UTHSCSA medical students | UTHSCSA | |
| Service-based learning | |||
| 8/2008 - Present | Immunology | The University of Texas Health Science Center | |
| Fundamental Concepts in Microbiology and Immunology | |||
| 6/2008 - Present | Service-based learning for health care professionals - ELEC 5044 Healthy Choices for Kids | UTHSCSA | |
| This offering is through the Center for Medical Humanities and Ethics. It involves group teaching of clinical service care provision to medical students, house officers and fellows in rural clinics in the San Antonio area, Rio Grande Valley, Haiti and the Dominican Republic. | |||
| 1/2008 - Present | Core Concepts in Microbiology & Immunology | The University of Texas Health Science Center | |
| Teaching graduate students Fundamental Concepts in Microbiology and Immunology. Micr 5003/5027 | |||
| 1/2008 - Present | Pre-Doctoral Student Supervision | UTHSCSA | |
| 1/2007 - Present | Pre-Doctoral Student Supervision | UTHSCSA | |
Journal Article |
| Text book: Curiel TJ, ed 478 pages. Cancer Immune Therapy: Practice, Promise and Paradigms 2013 Jan;. |
| Collins-Burow, B.M., Antoon, J.W., Frigo, D.E., Elliot, S., Weldon, C.B., Boue, S.M., Beckman, B.S., Curiel, T.J., Alam, J., McLachlan, J.A , Burow, M.E. "Antiestrogenic activity of flavonoid phytochemicals mediated via c-jun N-terminal protein kinase pathway: cell-type specific regulation of estrogen receptor alpha" PMID 22634477 J. Steroid Biochem & Mol Biol 2012 Jan;132(1-2):186-193. |
| Curiel TJ. "A useful strategy to help combat multidrug resistance" PMID 22483359 Drug Resistance Updates 2012 Jan;:106-113. |
| Hurez VJ, Dr. Daniel BJ, Sun L , Liu A, Ludwig S, Kious M, Thibodeaux SR, Pandeswara S, Murthy K , Livi C, Wall S, Brumlik MJ, Shin T, Zhang B, Curiel TJ. "Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice" PMID: 22496463 Cancer Research 2012 Jan;72:2089-2099. |
| Menetrier-Caux, C., T. Curiel, J. Faget, M. Manuel, C. Caux, and W. Zou. "Targeting regulatory T cells" PMID 22327882 Target Oncol 2012 Jan;7:15-28. |
| Tomihara K, Shin T, Hurez VJ, Yagita H, Pardoll DM, Zhang B, Curiel TJ, Shin T. "Aging-associated B7-DC B cells enhance anti-tumor immunity via Th1 and Th17 induction" PMID 22044484 Aging Cell 2012 Jan;11:128-138. |
| Lishi Sun, Vincent Hurez, Suzanne R. Thibodeaux, Mark J. Kious, Aijie Liu, Peiyi Lin, Kruthi Murthy, Srilakshmi Pandeswara, Tahiro Shin, Tyler Curiel. "Aged regulatory T cells protect from autoimmune inflammation despite reduced STAT3 activation and decreased constraint of IL-17 producing T cells" PMID 22372596 Aging Cell 2012 Jan;11(3):509-519. |
| Tomihara K, Shin T, Hurez VJ, Yagita H, Pardoll DM, Zhang B, Curiel TJ, Shin T. Aging-associated B7-DC(+) B cells enhance anti-tumor immunity via Th1 and Th17 induction. PMID 22044484 Aging Cell 2011 Nov;:129-138. |
| Brumlik MJ, Pandeswara S, Ludwig SM, Murthy K, Curiel TJ. "Parasite mitogen-activated protein kinases as drug discovery targets to treat human protozoan pathogens." PMID 21637385 J Signal Transduct 2011 Feb;2011:971968-971968. |
| Thibodeaux, S.R, and Curiel, T.J. "Immune Therapy for Ovarian Cancer: Promise and Pitfalls" PMID 21557637 International Reviews of Immunology 2011 Jan;30(2-3):102-119. |
| Rhodes, L.V., Short, S., Collins-Burow, B.M., Wadsworth, S., Beckman, B.S., Curiel, T.J., Hung, M., Richmond, A., Burow, M.E. "CXCR4 Mediates Estrogen Independent Growth, Metastasis, and Endocrine Therapy Resistance in Breast Cancer" PMID 21123450 Cancer Research 2011 Jan;71(2). |
| Michael J. Brumlik, Srilakshmi Pandeswara, Sara M. Ludwig, Kruthi Murthy, and Curiel TJ. "Parasite Mitogen-Activated Protein Kinases as Drug Discovery Targets to Treat Human Protozoan Pathogens" PMID 21637385 Article ID 971968, 2011. doi:10.1155/2011/971968 Journal of Signal Transduction 2011 Jan;2011. |
| Wang, L., Fan, J., Thompson, L.F., Zhang, Y., Shin, T., Curiel, T.J., Zhang, B. "Distinct roles for CD73 on nonhematopoietic and hematopoietic cells in mediating immune barriers that favor tumor growth in mice" PMID 21537079 Journal of Clinical Investigation 2011 Jan;121(6):2371-2382. |
| Brumlik, M.J., Nkhoma, S., Kious, M., Thompson, G., Patterson, T., Siekierka, J., Anderson, T., Curiel, TJ. "Human p38 mitogen-activated protein kinase inhibitor drugs inhibit Plasmodium falciparum replication" PMID 21338604 Experimental Parasitology 2011 Jan;:170-175. |
| Chakravarty D, Roy SS, Ram Babu C, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK and Ratna K. Vadlamudi. "Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis" PMID 21537079 Clinical Cancer Research 2011 Jan;17(8):2250-2259. |
| Daniel BJ, Pandeswara S, Brumlik MJ, Liu A, Thibodeaux SR, Ludwig SM, Sun X, Curiel TJ. "A simple method to detect Toxoplasma gondii-specific cytotoxic T cells in vivo." PMID 20149795 J Immunol Methods 2010 Apr;355(1-2):86-90. |
| Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B. "CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression." PMID 20179192 Cancer Res 2010 Mar;70(6):2245-2255. |
| Wang, L., Fan, J., Thompson, L.F., Zhang, Y., Shin, T., Curiel, T.J., Zhang, B. "Distinct roles for CD73 on nonhematopoietic and hematopoietic cells in mediating immune barriers that favor tumor growth in mice" PMID: 21537079 Journal of Clinical Investigation 2010 Jan;121(6):2371-2382. |
| Curiel TJ, Lin, P. Y., Sun, L., Thibodeaux, S.R, Ludwig, S. M., Vadlamudi, R. K., Hurez, V. J., Bahar, R., Kious, M. J., Livi, C. B., Wall, S. R., Chen, L., Zhang, B., Shin, T.,. "B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses" PMID 20686128 J Immunol 2010 Jan;185(5):2747-2753. |
| Tomihara K, Guo M, Shin T, Sun X, Ludwig SM, Brumlik MJ, Zhang B, Curiel TJ, Shin T. "Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b+Gr-1+ cells" PMID 20427766 J Immunol 2010 Jan;184(11):6151-6160. |
| Curiel TJ. "Translating basic immunomodulatory concepts into clinical application" Clinical Advances in Hematology 2009 Jan;7(1):9-10. |
| Curiel TJ. "Regulatory T cells and treatment of cancer." PMID 18508251 Curr Opin Immunol 2008 Apr;20(2):241-246. |
| Wei, S., Curiel, T., Coukos, G., Liu, R., Zou, W. "Inhibitory B7 family members in human ovarian carcinoma" PMID 18546634 Adv Exp Med Biol 2008 Jan;622:261-271. |
| Padmanabhan, S., Ravella, S., Curiel, T., Giles, F. "Current status of therapy for chronic myeloid leukemia: a review of drug development" PMID 18518762 Future Oncol 2008 Jan;4(3):359-377. |
| Wei S, Daniel BJ, Brumlik MJ, Burow ME, Zou W, Khan IA, Wadsworth S, Siekierka J, Curiel TJ. "Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection." PMID 17923491 Antimicrob Agents Chemother 2007 Dec;51(12):4324-4328. |
| Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. "IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity." PMID 17616639 Blood 2007 Nov;110(9):3192-3201. |
| Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G, Lackner A, Carmeliet P, Zou W. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. PMID 15313886 Cancer Res 2004 Aug;64(16):5535-5538. |
Review Article |
| Ruter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, Zou W, Curiel TJ. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. PMID 19273160 Front Biosci 2009 Jan;14:1761-1770. |
| Barnett BG, Rter J, Kryczek I, Brumlik MJ, Cheng PJ, Daniel BJ, Coukos G, Zou W, Curiel TJ. Regulatory T cells: a new frontier in cancer immunotherapy. PMID 18546633 Adv Exp Med Biol 2008 Jan;622:255-260. |
| Brumlik MJ, Daniel BJ, Waehler R, Curiel DT, Giles FJ, Curiel TJ. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy. PMID 18095930 Expert Opin Drug Deliv 2008 Jan;5(1):87-103. |
Federal |
|
| Funding Agency | NIH/NCI |
| Title | National Cancer Institute/CTRC |
| Status | Active |
| Period | 10/2009 - 9/2014 |
| Role | Principal Investigator |
| Grant Detail | This is a Cancer Center Support Grant that provides infrastructure support to members of the cancer center for the conducting of their cancer-related research. |
| Funding Agency | NIH/NIA |
| Title | Can Rapamycin Retard Age-Related Diseases? (In a 1 year no cost extension)(Dr. Ikeno was originally on this for 5% effort but during no cost was dropped to 1%) |
| Status | Active |
| Period | 7/2009 - 7/2012 |
| Role | Co-Investigator |
| Grant Detail | The recent report that rapamycin increases the lifespan of mice is a major breakthrough in aging because it can be translated easily to humans. However, the critical question is whether long-term rapamycin treatment improves healthspan/quality-of-life as well as lifespan. |
| Funding Agency | NIH |
| Title | A novel MAPK family in T. gondii |
| Status | Active |
| Period | 4/2005 - 3/2012 |
| Role | Principal Investigator |
| Grant Detail | |
| Funding Agency | NCI |
| Title | Plasmacytoid dendritic cell behavior in ovarian cancer |
| Status | Active |
| Period | 7/2005 - 6/2011 |
| Role | Principal Investigator |
| Grant Detail | |
| Funding Agency | FDA |
| Title | Phase II trial of Ontak to treat ovarian cancer under BB-IND 12345 |
| Status | Active |
| Period | 3/2006 - 3/2011 |
| Role | Principal Investigator |
| Grant Detail | from Tulane University |
Private |
|
| Funding Agency | Voelcker Family |
| Title | Improved immune therapy for cancer for therapy in the aged |
| Status | Active |
| Period | 7/2010 - 7/2013 |
| Role | Co-Investigator |
| Grant Detail | Improved immune therapy for cancer for therapy in the aged. |